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Heart disease remains the number one cause of death
in developed countries. Loss of cardiomyocytes (CMs)
due to aging or pathophysiological conditions (for
example, myocardial infarction) is generally considered
irreversible, and can lead to lethal conditions from
cardiac arrhythmias to heart failure. Human
pluripotent stem cells (PSCs), including embryonic
stem cells and induced pluripotent stem cells (iPSCs),
can self-renew while maintaining their pluripotency to
differentiate into all cell types, including CMs. As such,
PSCs represent an unprecedented unlimited ex vivo
cell source. In the present thematic series, we have
solicited seven review articles to discuss the current
state-of-the-art PSC-based approaches for such
applications as disease modeling, discovery of novel
drugs and therapeutics, cardiotoxicity screening and
cell-based myocardial repair, as well as the associated
hurdles and potential solutions.there are hurdles that need to be overcome. A well-
recognized roadblock has been the immaturity of PSC-In the first article by Jean-Sabastian Hulot and colleagues,
the authors review a list of parameters that need to be
considered for launching clinical trials of PSC-derived
CMs [1]. These include the need for good manufacturing
practice clinical grade cells, immunological consideration,
an efficient cardiac differentiation protocol, purification
of chamber-specific derived PSC-CMs, and optimized
delivery methods for improved retention, survival and
engraftment of the transplanted cells or tissues. The
advantages and limitations of using large animal models
such as porcine and non-human primates for pre-clinical
testing are also discussed.
Hung-Fat Tse and Song-Yan Liao review the pros and
cons of using multi-potent (adult) stem cells and PSCs
for heart regeneration [2]. Specifically, human skeletalCorrespondence: ronaldli@hku.hk
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2014muscle myoblasts, bone marrow-derived cells, endothelial
progenitor cells, mesenchymal stem cells and cardiac resi-
dent stem cells are compared with human embryonic stem
cells and iPSCs. In brief, while adult stem cells represent a
conceptually attractive autologous option, their ability to
regenerate the myocardium appears to be limited.
While any stem cell-based clinical translations are going
to take time because of defined regulatory processes that
need to be followed, recent technological advances have
enabled PSC-CMs to immediately serve as excellent
in vitro diagnostic tools for drug discovery, toxicity
screening and disease modeling. Arun Sharma, Sean Wu
and Joseph Wu review the use of iPSCs for disease model-
ing and drug screening [3]. In their article, the LEOPARD
syndrome, long QT syndromes, catecholaminergic poly-
morphic ventricular tachycardia, hereditary dilated and
hypertrophic cardiomyopathy and arrhythmogenic right
ventricular dysplasia/cardiomyopathy, which have been
modeled using iPSCs, are given as specific examples.
Despite the promises of iPSC technology, however,
CMs. The review article by Wendy Keung, Kenneth
Boheler and Ronald Li summarizes the immature struc-
tural, electrophysiological, calcium-handling, bioener-
getic and metabolic properties of PSC-CMs as well as
our current understanding of their underlying molecular
bases [4]. Based on this knowledge, in vitro approaches
that focus on such developmental cues as neurohormones,
epigenetic, micro-RNA and transcriptomic cues, and
non-cell autonomous microenvironmental factors (for
example, electrical and mechanical stimuli) have been
accordingly developed to recreate niche environments
for driving maturation. Along this line, Ken Boheler and
colleagues [5] describe in their article how various phys-
ical parameters such as bio-scaffold, cell alignment and
three-dimensional environments can contribute to the
maturation and functionality of PSC-CMs.
Pragmatically, the use of PSC-CMs for in vitro diag-
nostics and/or cell-based therapies can be realized only
if these cells can be mass produced with high standards
of quality control. Steve Oh and colleagues [6] reviewan Open Access article distributed under the terms of the Creative Commons
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able production of human PSC-CMs. Two-dimensional
monolayer cell culture, cell-aggregate and microcarrier
are compared in the context of platform selection, bio-
process parameters, medium development, downstream
processing and parameters that meet current good
manufacturing practice standards.
Although human PSC-based heart regeneration is a
new concept and discipline with a relatively short history
of about a decade, significant scientific and technical
advances are being made at remarkably rapid rates,
ushering in a new era of cardiovascular bio-engineering
and regenerative medicine. It is with every optimism
that the knowledge gained during the process not only
enables a better basic understanding of the human
heart but will also translate into tangible healthcare
benefits in the not too distant future.Note: This article is part of a thematic series on Cardiovascular
regeneration edited by Ronald Li. Other articles in the series can
be found online at http://stemcellres.com/series/cardiovascular.Abbreviations
CM: Cardiomyocyte; iPSC: Induced pluripotent stem cell; PSC: Pluripotent
stem cell.
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